Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 0
---
TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where such offer or sale is not permitted.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-284980 Subject to Completion, dated February 18, 2025 PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus dated February 14, 2025) $ AbbVie Inc. $ % SENIOR NOTES DUE 20
$ % SENIOR NOTES DUE 20
$ % SENIOR NOTES DUE 20
$ % SENIOR NOTES DUE 20 Interest on each series of Notes is payable on and of each year,
commencing , 2025. AbbVie Inc., a Delaware corporation (the “ Company ” or the “ Issuer ”), is offering $ aggregate principal amount of its % senior notes due 20 (the “ 20 Notes ”), $ aggregate principal amount of its % senior notes due 20 (the “ 20 Notes ”), $ aggregate principal amount of its % senior notes due 20 (the “ 20 Notes ”) and $ aggregate principal amount of its % senior notes due 20 (the “ 20 Notes ,” and together with the 20 Notes, the 20 Notes and the 20 Notes, the “ Notes ”). Each of the 20 Notes, the 20 Notes, the 20 Notes and the 20 Notes is referred to as a “series” of Notes. The Notes will be unsecured, unsubordinated obligations of the Company and will rank equally in right of payment with all of the Company’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. The Notes will be issued in minimum denominations of $2,000 and in integral multiples of $1,000 in excess thereof. The Notes will not be listed on any securities exchange. Currently there is no public market for any series of the Notes. The Company expects the net proceeds to it from this offering will be approximately $ billion (after deducting underwriting discounts and its estimated offering expenses). The Company intends to use the net proceeds from the sale of the Notes, together with cash on hand, (a) to repurchase, redeem, satisfy and